Latest Shareholder Approval News

Kalium Lakes Limited reports progress on its recapitalisation plan following operational setbacks and administration, while shares remain suspended on the ASX.

Fin Resources Limited reports steady progress in lithium and uranium exploration across its Canadian and Australian projects, while managing a lean cash position and evaluating funding options.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Classic Minerals Limited has agreed to sell its Kat Gap gold tenements to Bain Global Resources for A$7 million, aiming to reduce debt and refocus on other exploration projects. The deal awaits shareholder approval and regulatory clearances.

South Harz Potash Limited has made significant strides in acquiring the Sollstedt mine and secured approximately A$2.2 million in new equity, positioning itself to advance the Ohmgebirge project amid a strengthening potash market.

Lodestar Minerals has acquired an option over the high-grade Darwin IOCG project in Chile, revealing exceptional surface assays and preparing for drilling in early 2025. The company also identified new copper targets in Western Australia’s Earaheedy project and secured $520,000 in funding to advance exploration.

Epsilon Healthcare's December 2023 quarterly report reveals significant boardroom conflict and governance breaches, yet operational segments show promising growth.

LCL Resources has executed a binding agreement to divest its Colombian assets for A$10 million, while confirming a significant copper-gold porphyry discovery at its Dada project in Papua New Guinea.

Triton Minerals has secured A$17 million from the sale of a 70% stake in its Mozambique graphite assets, while progressing environmental approvals and unveiling promising high-grade gold and copper results at its new Aucu project.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

GBM Resources reports robust progress in its Queensland and South Australian gold projects, highlighted by a $12 million farm-in deal at Twin Hills and positive cash flow from White Dam. Exploration strategies and corporate restructuring set the stage for a pivotal 2025.

Great Southern Mining Limited reports promising assay results from its Duketon Gold Project, extending high-grade gold mineralisation and identifying new anomalies, alongside a $2.4 million capital raise to fund ongoing exploration.